Medline Q3 Sales Up 10.4% to $7.9B; Raises Organic Sales Guidance and Authorizes $1B Buyback
MDLN sits 18% above its 52-week low of $31.37.
Summary
Medline grew Q3 sales 10.4% to $7.9 billion and raised full-year organic sales guidance, while nine-month net income fell 28.8% on Tracy fire costs. The board also authorized a $1 billion buyback and the company prepaid $750 million of debt.
Key Events · Earnings and Guidance · MDLN
-
Q3 Sales Up 10.4% to $7.9B
Third quarter net sales rose to $7,856 million from $7,115 million, with Organic Sales up 10.5%. Q3 net income slipped 1.2% to $318 million and Adjusted EBITDA rose 11.8% to $960 million.
-
Full-Year Organic Sales Guidance Raised
2026 Organic Sales growth outlook lifted to 10.0%-10.5% from 9.0%-10.0%; Adjusted EBITDA guidance of $3.3 billion to $3.4 billion reaffirmed and excludes $324 million of net IEEPA tariff refunds booked in the first nine months.
-
$1B Buyback and $750M Debt Prepayment
Board authorized repurchases of up to $1 billion of Class A common stock and/or Medline Holdings units; the company also prepaid $750 million of the 2033 Refinancing Term Loan Facility. Net leverage stood at 2.5x on $9.1 billion of net debt.
-
Nine-Month Net Income Down 28.8%
Net income fell to $696 million from $977 million, including $316 million of net losses related to the Tracy, California distribution center fire, plus higher tariff-related cost of goods and inventory inflation. Free cash flow was $1.8 billion.
Analysis · MDLN · Industrial Applications And Services
Sales growth is holding at double digits, and management lifted the full-year organic sales range to 10.0%-10.5% from 9.0%-10.0% while keeping the $3.3B-$3.4B Adjusted EBITDA outlook. The profit picture is messier: nine-month net income fell 28.8% to $696 million, dragged by $316 million of net losses from the Tracy distribution center fire, higher tariff-laden cost of goods and inflation in inventory costs. Against that, the board authorized up to $1 billion of buybacks and the company prepaid $750 million of its 2033 term loan, which tells you cash generation ($1.8 billion of free cash flow in nine months) is strong enough to fund both. For a company that has spent the past month dealing with FDA warnings on its branded beds and a securities-fraud investigation, the capital-return and debt-reduction moves are the more consequential part of this release.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDLN was trading at $37.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $44.8B. The 52-week trading range was $31.37 to $50.88. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.